Activation of Wnt signaling promotes olaparib resistant ovarian cancer

Tomomi M. Yamamoto, Alexandra McMellen, Zachary L. Watson, Jennifer Aguilera, Rebecca Ferguson, Elmar Nurmemmedov, Tanay Thakar, George-Lucian Moldovan, Hyunmin Kim, Diana M. Cittelly, Annette M. Joglar, Elyse P. Brennecke, Heidi Wilson, Kian Behbakht, Matthew J. Sikora, Benjamin G. Bitler

Research output: Contribution to journalArticle

Abstract

Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or niraparib) represent an emerging treatment strategy. While PARPi are most effective in homologous recombination DNA repair-deficient (HRD) HGSOCs, recent studies have observed a significant benefit in non-HRD HGSOCs. However, all HGSOC patients are likely to acquire resistance. Therefore, there is an urgent clinical need to understand PARPi resistance and to introduce novel combinatorial therapies to manage PARPi resistance and extend HGSOC disease-free intervals. In a panel of HGSOC cell lines, we established matched olaparib sensitive and resistant cells. Transcriptome analysis of the matched olaparib-sensitive vs -resistant cells revealed activation of the Wnt signaling pathway and consequently increased TCF transcriptional activity in PARPi-resistant cells. Forced activation of canonical Wnt signaling in several PARPi-sensitive cells via WNT3A reduced olaparib and rucaparib sensitivity. PARPi resistant cells were sensitive to inhibition of Wnt signaling using the FDA-approved compound, pyrvinium pamoate, which has been shown to promote downregulation of β-catenin. In both an HGSOC cell line and a patient-derived xenograft model, we observed that combining pyrvinium pamoate with olaparib resulted in a significant decrease in tumor burden. This study demonstrates that Wnt signaling can mediate PARPi resistance in HGSOC and provides a clinical rationale for combining PARP and Wnt inhibitors.

Original languageEnglish (US)
Pages (from-to)1770-1782
Number of pages13
JournalMolecular Carcinogenesis
Volume58
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Ovarian Neoplasms
Carcinoma
Ovarian Diseases
Recombinational DNA Repair
Cell Line
Catenins
Wnt Signaling Pathway
Gene Expression Profiling
olaparib
Platinum
Tumor Burden
Heterografts
Therapeutics
Down-Regulation
Drug Therapy
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cancer Research

Cite this

Yamamoto, T. M., McMellen, A., Watson, Z. L., Aguilera, J., Ferguson, R., Nurmemmedov, E., ... Bitler, B. G. (2019). Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis, 58(10), 1770-1782. https://doi.org/10.1002/mc.23064
Yamamoto, Tomomi M. ; McMellen, Alexandra ; Watson, Zachary L. ; Aguilera, Jennifer ; Ferguson, Rebecca ; Nurmemmedov, Elmar ; Thakar, Tanay ; Moldovan, George-Lucian ; Kim, Hyunmin ; Cittelly, Diana M. ; Joglar, Annette M. ; Brennecke, Elyse P. ; Wilson, Heidi ; Behbakht, Kian ; Sikora, Matthew J. ; Bitler, Benjamin G. / Activation of Wnt signaling promotes olaparib resistant ovarian cancer. In: Molecular Carcinogenesis. 2019 ; Vol. 58, No. 10. pp. 1770-1782.
@article{8827421b4e0148e591704807464950bb,
title = "Activation of Wnt signaling promotes olaparib resistant ovarian cancer",
abstract = "Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or niraparib) represent an emerging treatment strategy. While PARPi are most effective in homologous recombination DNA repair-deficient (HRD) HGSOCs, recent studies have observed a significant benefit in non-HRD HGSOCs. However, all HGSOC patients are likely to acquire resistance. Therefore, there is an urgent clinical need to understand PARPi resistance and to introduce novel combinatorial therapies to manage PARPi resistance and extend HGSOC disease-free intervals. In a panel of HGSOC cell lines, we established matched olaparib sensitive and resistant cells. Transcriptome analysis of the matched olaparib-sensitive vs -resistant cells revealed activation of the Wnt signaling pathway and consequently increased TCF transcriptional activity in PARPi-resistant cells. Forced activation of canonical Wnt signaling in several PARPi-sensitive cells via WNT3A reduced olaparib and rucaparib sensitivity. PARPi resistant cells were sensitive to inhibition of Wnt signaling using the FDA-approved compound, pyrvinium pamoate, which has been shown to promote downregulation of β-catenin. In both an HGSOC cell line and a patient-derived xenograft model, we observed that combining pyrvinium pamoate with olaparib resulted in a significant decrease in tumor burden. This study demonstrates that Wnt signaling can mediate PARPi resistance in HGSOC and provides a clinical rationale for combining PARP and Wnt inhibitors.",
author = "Yamamoto, {Tomomi M.} and Alexandra McMellen and Watson, {Zachary L.} and Jennifer Aguilera and Rebecca Ferguson and Elmar Nurmemmedov and Tanay Thakar and George-Lucian Moldovan and Hyunmin Kim and Cittelly, {Diana M.} and Joglar, {Annette M.} and Brennecke, {Elyse P.} and Heidi Wilson and Kian Behbakht and Sikora, {Matthew J.} and Bitler, {Benjamin G.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1002/mc.23064",
language = "English (US)",
volume = "58",
pages = "1770--1782",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "10",

}

Yamamoto, TM, McMellen, A, Watson, ZL, Aguilera, J, Ferguson, R, Nurmemmedov, E, Thakar, T, Moldovan, G-L, Kim, H, Cittelly, DM, Joglar, AM, Brennecke, EP, Wilson, H, Behbakht, K, Sikora, MJ & Bitler, BG 2019, 'Activation of Wnt signaling promotes olaparib resistant ovarian cancer', Molecular Carcinogenesis, vol. 58, no. 10, pp. 1770-1782. https://doi.org/10.1002/mc.23064

Activation of Wnt signaling promotes olaparib resistant ovarian cancer. / Yamamoto, Tomomi M.; McMellen, Alexandra; Watson, Zachary L.; Aguilera, Jennifer; Ferguson, Rebecca; Nurmemmedov, Elmar; Thakar, Tanay; Moldovan, George-Lucian; Kim, Hyunmin; Cittelly, Diana M.; Joglar, Annette M.; Brennecke, Elyse P.; Wilson, Heidi; Behbakht, Kian; Sikora, Matthew J.; Bitler, Benjamin G.

In: Molecular Carcinogenesis, Vol. 58, No. 10, 01.10.2019, p. 1770-1782.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activation of Wnt signaling promotes olaparib resistant ovarian cancer

AU - Yamamoto, Tomomi M.

AU - McMellen, Alexandra

AU - Watson, Zachary L.

AU - Aguilera, Jennifer

AU - Ferguson, Rebecca

AU - Nurmemmedov, Elmar

AU - Thakar, Tanay

AU - Moldovan, George-Lucian

AU - Kim, Hyunmin

AU - Cittelly, Diana M.

AU - Joglar, Annette M.

AU - Brennecke, Elyse P.

AU - Wilson, Heidi

AU - Behbakht, Kian

AU - Sikora, Matthew J.

AU - Bitler, Benjamin G.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or niraparib) represent an emerging treatment strategy. While PARPi are most effective in homologous recombination DNA repair-deficient (HRD) HGSOCs, recent studies have observed a significant benefit in non-HRD HGSOCs. However, all HGSOC patients are likely to acquire resistance. Therefore, there is an urgent clinical need to understand PARPi resistance and to introduce novel combinatorial therapies to manage PARPi resistance and extend HGSOC disease-free intervals. In a panel of HGSOC cell lines, we established matched olaparib sensitive and resistant cells. Transcriptome analysis of the matched olaparib-sensitive vs -resistant cells revealed activation of the Wnt signaling pathway and consequently increased TCF transcriptional activity in PARPi-resistant cells. Forced activation of canonical Wnt signaling in several PARPi-sensitive cells via WNT3A reduced olaparib and rucaparib sensitivity. PARPi resistant cells were sensitive to inhibition of Wnt signaling using the FDA-approved compound, pyrvinium pamoate, which has been shown to promote downregulation of β-catenin. In both an HGSOC cell line and a patient-derived xenograft model, we observed that combining pyrvinium pamoate with olaparib resulted in a significant decrease in tumor burden. This study demonstrates that Wnt signaling can mediate PARPi resistance in HGSOC and provides a clinical rationale for combining PARP and Wnt inhibitors.

AB - Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or niraparib) represent an emerging treatment strategy. While PARPi are most effective in homologous recombination DNA repair-deficient (HRD) HGSOCs, recent studies have observed a significant benefit in non-HRD HGSOCs. However, all HGSOC patients are likely to acquire resistance. Therefore, there is an urgent clinical need to understand PARPi resistance and to introduce novel combinatorial therapies to manage PARPi resistance and extend HGSOC disease-free intervals. In a panel of HGSOC cell lines, we established matched olaparib sensitive and resistant cells. Transcriptome analysis of the matched olaparib-sensitive vs -resistant cells revealed activation of the Wnt signaling pathway and consequently increased TCF transcriptional activity in PARPi-resistant cells. Forced activation of canonical Wnt signaling in several PARPi-sensitive cells via WNT3A reduced olaparib and rucaparib sensitivity. PARPi resistant cells were sensitive to inhibition of Wnt signaling using the FDA-approved compound, pyrvinium pamoate, which has been shown to promote downregulation of β-catenin. In both an HGSOC cell line and a patient-derived xenograft model, we observed that combining pyrvinium pamoate with olaparib resulted in a significant decrease in tumor burden. This study demonstrates that Wnt signaling can mediate PARPi resistance in HGSOC and provides a clinical rationale for combining PARP and Wnt inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85071676158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071676158&partnerID=8YFLogxK

U2 - 10.1002/mc.23064

DO - 10.1002/mc.23064

M3 - Article

C2 - 31219654

AN - SCOPUS:85071676158

VL - 58

SP - 1770

EP - 1782

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 10

ER -

Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis. 2019 Oct 1;58(10):1770-1782. https://doi.org/10.1002/mc.23064